These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 11193883

  • 1. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
    Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M.
    Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Apr 15; 162(8):4685-96. PubMed ID: 10202009
    [Abstract] [Full Text] [Related]

  • 3. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
    Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP.
    J Neuroimmunol; 1999 Sep 01; 99(1):61-71. PubMed ID: 10496178
    [Abstract] [Full Text] [Related]

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Feb 01; 162(3):1707-16. PubMed ID: 9973433
    [Abstract] [Full Text] [Related]

  • 5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar 01; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
    Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D.
    J Biol Chem; 1998 Nov 20; 273(47):31427-36. PubMed ID: 9813054
    [Abstract] [Full Text] [Related]

  • 7. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Neuroimmunol; 1999 May 03; 96(2):167-81. PubMed ID: 10337915
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M, Ganea D.
    J Immunol; 2000 Sep 15; 165(6):3051-7. PubMed ID: 10975815
    [Abstract] [Full Text] [Related]

  • 9. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F, Puech R, Bockaert J, Brabet P, Bertrand G.
    Endocrinology; 2002 Apr 15; 143(4):1253-9. PubMed ID: 11897681
    [Abstract] [Full Text] [Related]

  • 10. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
    Kim WK, Kan Y, Ganea D, Hart RP, Gozes I, Jonakait GM.
    J Neurosci; 2000 May 15; 20(10):3622-30. PubMed ID: 10804204
    [Abstract] [Full Text] [Related]

  • 11. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L, Ahrén B, Edgren G, Degerman E.
    Endocrinology; 2005 Feb 15; 146(2):744-50. PubMed ID: 15514088
    [Abstract] [Full Text] [Related]

  • 12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
    Delgado M, Ganea D.
    J Biol Chem; 2001 Jan 05; 276(1):369-80. PubMed ID: 11029467
    [Abstract] [Full Text] [Related]

  • 13. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O, Junicho A, Akashi T, Koizumi K, Matsuda T, Fuse H, Saiki I.
    Oncol Rep; 2005 Jun 05; 13(6):1217-21. PubMed ID: 15870945
    [Abstract] [Full Text] [Related]

  • 14. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M, Jonakait GM, Ganea D.
    Glia; 2002 Aug 05; 39(2):148-61. PubMed ID: 12112366
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
    Sun W, Tadmori I, Yang L, Delgado M, Ganea D.
    J Neuroimmunol; 2000 Jul 10; 107(1):88-99. PubMed ID: 10808055
    [Abstract] [Full Text] [Related]

  • 16. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
    Ekblad E, Jongsma H, Brabet P, Bockaert J, Sundler F.
    Ann N Y Acad Sci; 2000 Jul 10; 921():137-47. PubMed ID: 11193817
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M, Ganea D.
    J Immunol; 2001 Jul 15; 167(2):966-75. PubMed ID: 11441105
    [Abstract] [Full Text] [Related]

  • 18. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
    Drahushuk K, Connell TD, Higgins D.
    J Neurosci; 2002 Aug 01; 22(15):6560-9. PubMed ID: 12151535
    [Abstract] [Full Text] [Related]

  • 19. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
    Delgado M, Ganea D.
    J Neuroimmunol; 2000 Oct 02; 110(1-2):97-105. PubMed ID: 11024538
    [Abstract] [Full Text] [Related]

  • 20. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM, Carmena MJ, Busto R, Sánchez-Chapado M, Guijarro LG, Prieto JC.
    Cell Signal; 1999 Nov 02; 11(11):813-9. PubMed ID: 10617284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.